There are some truly innovative therapeutic techniques in the works that can transform the future of medicine, and one of them is anti-VEGF. This anti-angiogenic therapy can cure a variety of cancers and retinal diseases that were previously incurable using biomolecules that can suppress VEGF signaling pathways, thereby preventing metastasis in cancers and irreversible blindness in retinal diseases. Since the advent of the 21st century, several anti-VEGF monoclonal antibody treatments — such as Bevacizumab, Ranibizumab, and Aflibercept — and another form of treatment known as Tyrosine Kinase Inhibitors — such as Sunitinib, Sorafenib and Pazopanib — have been developed and distributed, however further research and experimenting is required to enhance the efficacy of these treatments. This informative medical handbook first explains the role that VEGF plays in cancer proliferation and retinal disease progression before explaining the common anti-VEGF treatments as well as their mechanisms of action on the molecular level using comprehendible explanations and diagrams that anyone — whether a student wishing to learn more about new medical innovations, an aspiring medical scientist, or a qualified doctor — can understand. The handbook is also intended to provide a comprehensive reference for medical researchers wishing to write medical papers on the topic of anti-VEGF treatments, and is therefore highly recommended for such individuals.
